# GRIN Therapeutics funding rounds and investors

As of 14 Oct 2026, GRIN Therapeutics has raised $140M across 1 verified round on record; latest: $140 million Series D+, announced 27 May 2025.

GRIN Therapeutics develops precision therapeutics targeting neurodevelopmental disorders resulting from NMDA receptor dysfunction, focusing primarily on pediatric patients.

Website: https://grintherapeutics.com  
Page: https://fireround.dev/companies/grintherapeutics.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-05-27 | Series D+ | $140 million | not stated | Angelini Pharma, Blackstone Life Sciences | [prnewswire.com](https://www.prnewswire.com/news-releases/grin-therapeutics-and-angelini-pharma-enter-into-exclusive-collaboration-to-develop-and-commercialize-radiprodil-outside-north-america-302464677.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.